Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02360917 · ClinicalTrials.gov registry record · NA

Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment

A NA study of Cancer and Cognition, sponsored by Cedars-Sinai Medical Center.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT02360917: Completed NA study of Cancer and Cognition, sponsored by Cedars-Sinai Medical Center.

NCT02360917 is a NA study of Cancer and Cognition that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 31 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02360917, a NA study of Cancer and Cognition, has completed, sponsored by Cedars-Sinai Medical Center.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

At Cedars-Sinai Medical Center, we have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2 hours for 6 weeks. The leading neuropsychologist covers material such as guided relaxation, behavioral strategies for automatic/negative thoughts, compensatory strategies for attention and memory, executive functioning, pacing, and balance. Each Haze series will be electronically delivered in a live format to our satellite site, The University of Kansas.

Conditions Studied

Interventions

  • OTHER Emerging from the Haze

Study Locations (1)

California

  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2015-07-06
Est. Completion 2018-05-23
Phase NA
Cedars-Sinai Medical Center

339 total trials

What the finished NCT02360917 record still lists

NCT02360917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Emerging from the Haze is the first listed.

NCT02360917 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02360917 about?

NCT02360917 is a clinical study titled "Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment". At Cedars-Sinai Medical Center, we have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2 hours fo...

What is the current status of trial NCT02360917?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2015-07-06. Estimated completion is 2018-05-23.

What conditions does trial NCT02360917 study?

This clinical trial studies the following conditions: Cancer, Cognition.

What interventions are being tested in trial NCT02360917?

The interventions under investigation include: Emerging from the Haze (OTHER).

Who is sponsoring clinical trial NCT02360917?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02360917 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02360917's enrollment target sits among peer trials

31 499th of 615 higher than 115 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02360917, the US trial registry maintained by the National Library of Medicine. NCT02360917 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.